32 / 63
Demcizumab
: monoclonal anti-DLL4 (Notch ligand)
Rand P. II YOSHEMITE: Gem-Abraxane +/- Demcizumab
1
1.- Cubillo A et al. ESMO 2017
2.- O´Reilly E et al. ASCO-GI 2017
Tarextumab
: anti-Notch 2,3 mAb
Rand P. II : Gem-Abraxane +/- Tarextumab
2